ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
21 hedge funds and large institutions have $8.41M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 6 closing their positions.
1.73% more ownership
Funds ownership: 19.34% → 21.07% (+1.7%)
9% less funds holding
Funds holding: 23 → 21 (-2)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
60% less capital invested
Capital invested by funds: $20.9M → $8.41M (-$12.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$2.75M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$711K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$104K |
| 4 |
BWA
BDO Wealth Advisors
Jacksonville,
Florida
|
+$71.6K |
| 5 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
+$26.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$921K |
| 2 |
Morgan Stanley
New York
|
-$762K |
| 3 |
LPL Financial
San Diego,
California
|
-$751K |
| 4 |
Jane Street
New York
|
-$567K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$194K |
CNCR Hedge Fund Activity: Q1 2019 in Review
21 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2019, worth a combined $8.41M — down 60% from $20.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CNCR and 4 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was BCWM LLC, adding an estimated $2.75M. The largest seller was Susquehanna International Group, cutting an estimated $921K.
- 21 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2019, down from 23 in Q4 2018.
- Funds reported $8.41M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2019, down 60% quarter-over-quarter.
- 4 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2019 and 6 closed out, a net change of -2 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2019 was BCWM LLC, an estimated $2.75M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2019 was Susquehanna International Group, an estimated $921K sold.
Based on aggregated 13F filings for Q1 2019.